Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
作者信息
Ueda-Consolvo Tomoko, Ishida Masaaki, Nakamura Tomoko, Yanagisawa Shuichiro, Tsuboi Kotaro, Wakabayashi Taku, Hayashi Atsushi, Sharma Ashish
机构信息
Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, Japan.
出版信息
Eye (Lond). 2024 Nov;38(16):3193-3196. doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23.
Abstract
摘要
相似文献
1
Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
Eye (Lond). 2024 Nov;38(16):3193-3196. doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23.
2
Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.
Ophthalmol Ther. 2024 Oct;13(10):2629-2644. doi: 10.1007/s40123-024-01011-z. Epub 2024 Aug 10.
3
Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
Int J Retina Vitreous. 2021 Mar 24;7(1):24. doi: 10.1186/s40942-021-00293-w.
4
CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.
Clin Ophthalmol. 2025 Mar 28;19:1093-1102. doi: 10.2147/OPTH.S515479. eCollection 2025.
5
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.
BMC Ophthalmol. 2025 Jan 23;25(1):41. doi: 10.1186/s12886-025-03846-x.
6
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
7
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation.
Ophthalmol Ther. 2022 Feb;11(1):135-149. doi: 10.1007/s40123-021-00416-4. Epub 2021 Nov 5.
8
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.
Indian J Ophthalmol. 2021 Feb;69(2):347-351. doi: 10.4103/ijo.IJO_2516_20.
9
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
10
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2022 Jan;129(1):54-63. doi: 10.1016/j.ophtha.2021.04.031. Epub 2021 May 3.
引用本文的文献
1
Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.
Clin Ophthalmol. 2025 Jul 29;19:2505-2512. doi: 10.2147/OPTH.S542496. eCollection 2025.
2
Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).
Eye (Lond). 2025 May 3. doi: 10.1038/s41433-025-03813-2.
3
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.
J Vitreoretin Dis. 2025 Feb 27:24741264251322213. doi: 10.1177/24741264251322213.
本文引用的文献
1
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):851-859. doi: 10.1080/14712598.2023.2176218. Epub 2023 Feb 19.
2
Approved biosimilar ranibizumab-a global update.
Eye (Lond). 2023 Feb;37(2):200-202. doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16.
3
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.
Ophthalmologica. 2019;241(1):24-31. doi: 10.1159/000488602. Epub 2018 Jun 26.
Zotero 插件